35 - Preclinical Efficacy Models (S3E5)

All right, deep divers, get ready, because today
we are going to explore preclinical efficacy
models. We're going to unpack how scientists
determine if a new drug actually works before
it even gets to a point of human trials. You've
sent us some really fascinating stuff this time,
journal articles, FDA docs, even some case studies
from your own work at OPR &D. Yeah, it really
is like piecing together a puzzle. We gather
evidence from different sources to build a case
either for or against a drug's potential. I love
that analogy. And today's puzzle pieces come
from two main sources, in vivo and in vitro models.
Exactly. In vivo refers to testing on living
organisms, and often this means animal models,
mice, rats, even primates sometimes. And in vitro
involves controlled environments, so things like
test tubes or cell cultures. It's kind of like
testing a new fertilizer on a single plant in
a pot before you try it on a whole field. Precisely.
Each approach offers unique insights, but just
like you said, with your analogy, they also have
limitations. That makes sense. So let's just
start with the basics. Why are these preclinical
efficacy models so crucial? We can't just skip
ahead to human trials, right? Absolutely not.
Imagine building a skyscraper without testing
the foundation first. That's essentially what
it would be like to bypass preclinical testing.
So we need to gather enough evidence to justify
the risk and the expense of moving to human testing.
OK, that's a great way to put it. So then how
do scientists choose between in vivo and in vitro?
Is it like choosing the right tool for the job?
You hit the nail on the head. The choice depends
on a lot of different factors. The disease that's
being targeted, the drugs mechanism of action,
basically how it's supposed to work at the molecular
level, and of course, ethical considerations,
especially when we're talking about using animals.
Speaking of which, those OPRND cases that you
sent in, I noticed a few of them involved pre
-clinical models for Alzheimer's disease, and
those always seem particularly complex. They
are complex. One case that you sent in detailed
a study using a mouse model that was genetically
engineered to develop amyloid clacks. And those
are those protein clumps that are found in the
brains of Alzheimer's patients. Ah, so the researchers
created a model that closely mimics a key aspect
of the human disease. Exactly. And then they
tested a potential drug's ability to reduce those
plaques. And importantly, they observed the effects
on the mice's cognitive function. It's so fascinating
how scientists can... tailor these models to
specific diseases. It is, but we always have
to remember no model is perfect. And that's where
this idea of predictive power comes in. OK, tell
me more about that. I'm guessing it refers to
how accurately a model predicts what will happen
in humans. Exactly. A model with high predictive
power gives us more confidence that a drug's
effects that are observed in the model will translate
to humans. But I imagine that can be tricky to
assess, right? It can be tricky. Take those Alzheimer's
models, for instance. Mice and humans have very
different brains, both structurally and functionally.
So while a drug might reduce plaques in a mouse,
it doesn't guarantee it will do the same thing
in a human, let alone lead to improvements in
cognitive symptoms. Right. That highlights a
key point you made earlier. Every model has its
limitations. What are some of the other challenges
that researchers face? Well, with in vivo models,
like using animals, there are ethical considerations.
Of course, we have to keep those in mind always,
and then they can be really costly and time consuming
as well. That makes sense. What about limitations
of in vitro models? One major drawback is oversimplification.
You know, testing a drug on cells in a dish can't
fully replicate those intricate interactions
that are happening within a living organism.
It's like trying to understand a symphony by
listening to just a single instrument. A perfect
analogy, you might miss the nuances and the complexity
of the full composition. So a drug might work
great in a test tube, but then fail in an animal
because it can't actually effectively reach its
target within the body. Exactly. These limitations
really underscore why researchers carefully consider
both the strengths and the weaknesses of each
model they're using, often using multiple models
to get a more comprehensive understanding. That
brings me to another point. I noticed several
FDA and ICH guidelines in your materials. I'm
guessing those play a big role in making sure
that these models are being used effectively.
Absolutely. Regulatory bodies like the FDA and
the International Council for Harmonization,
they set really strict standards for preclinical
studies, and this ensures data quality, ethical
conduct, and ultimately patient safety. So they're
setting the bar high for what constitutes reliable
and meaningful results? Precisely. For instance,
there are very specific guidelines on selecting
and validating animal models, designing experiments,
and even how they're collecting and analyzing
the data and all these measures are aimed at
reducing bias and increasing the reliability
of preclinical research. That makes sense. So
it's not just about doing the research. It's
about doing it rigorously and transparently.
Those OPRND cases you sent in, do any of them
offer a glimpse into how these guidelines play
out in real -world research? They do. One case
involved a new antibiotic, and the researchers
initially tested the drug's bacteria -killing
ability in a Petri dish, which is a standard
in vitro approach. Makes sense, but I'm guessing
they didn't stop there. You're right. They also
tested the drug in mice that were infected with
the same bacteria to observe its effects within
a living system. This multifaceted approach,
guided by those regulatory standards, helps researchers
build a much stronger case for a drug's efficacy.
It's like using multiple lenses to examine a
specimen to gain a more complete picture. Exactly.
By combining in vitro and in vivo data, researchers
can identify potential benefits and risks early
on, and this allows them to make better more
informed decisions about which drugs should move
forward. So it's a crucial step in that whole
drug development journey. And understanding these
models is essential for anyone who's following
the latest medical advancement. Absolutely. Now
let's dig a little deeper into this concept of
efficacy. How do scientists actually measure
if a drug is working in a preclinical setting?
That's where things get really interesting. Well,
it all comes down to really understanding what
efficacy actually means in the context of preclinical
research. So we're not just looking for any effect.
We're searching for effects that are likely to
be meaningful in a clinical setting. So effects
that will translate to real benefits for human
patients. So it's not just enough to see a drug
working in a petri dish or even in a mouse. You
need to be confident that it will have a real
impact on human health. Precisely. And that's
where that concept of predictive power that we
talked about earlier really comes in. We want
to know how well those preclinical results. So
from both the in vivo and the in vitro studies
predict what will actually happen when the drug
is then tested in humans. And I'm guessing that's
not always easy to do. How do scientists actually
go about measuring efficacy in these preclinical
models? Well, it really depends on the disease
and the specific drug that's being investigated.
Sometimes it's pretty straightforward. Like in
a cancer model, for instance, we might measure
tumor size reduction. as a clear indicator of
the drug's effectiveness. Or in an infection
model, we could measure the reduction in bacterial
counts. OK. Those seem like pretty clear -cut
endpoints, things that are easy to measure and
directly relevant to the disease. They are. But
in other cases, measuring efficacy can be much
more complex. Think back to those Alzheimer's
models that we were talking about earlier. Measuring
a drug's impact on cognitive function is far
more challenging than simply measuring tumor
size. since cognition is such a multi -faceted
aspect of brain function. Exactly. It's not always
easy to pinpoint precisely how a drug is affecting
those intricate cognitive processes, even in
a controlled pre -clinical setting. So how do
researchers tackle that challenge? Are there
specific methods for measuring these more nuanced
effects? There are researchers often develop
very specialized behavioral tests that assess
various aspects of cognition, so things like
memory learning attention. And they very carefully
observe the animal's performance on these tasks
to gauge whether the drug is having a positive
impact. It sounds like they're almost becoming
animal psychologists. you know, carefully studying
behavior to understand the drug's effects. Yeah,
that's a great way to put it. And sometimes they
even use brain imaging techniques, you know,
similar to those used in human studies, to observe
changes in brain activity in response to the
drug. Wow, that's incredible. It really highlights
the ingenuity and the dedication that's required
to assess efficacy in these complex disease models.
But even with these very sophisticated techniques,
there's still a level of uncertainty, right?
We can't be 100 % certain that what we see in
a pre -clinical model will perfectly mirror what
happens in humans. You're absolutely right, and
that's where things can get even more complicated.
Sometimes researchers have to rely on what are
called surrogate endpoints, and these are measurements
that are thought to correlate with the actual
clinical outcome that we're interested in, but
they're not the outcome itself. Okay, that sounds
a bit abstract. Can you give me a more concrete
example of a surrogate endpoint? Sure. Imagine
a study of a new drug for heart disease instead
of directly measuring the drug's ability to prevent
heart attacks, which, you know, would be a very
long and complex study. Researchers might use
cholesterol levels as a surrogate endpoint because
we know that high cholesterol is a risk factor
for heart attacks. So if the drug effectively
lowers cholesterol, it's reasonable to assume
that it might also reduce the risk of heart attacks
down the line. It's like using a proxy measure,
something that's easier to measure in the short
term, but that's believed to be a good indicator
of the long -term outcome that we're ultimately
interested in. Exactly. And surrogate endpoints
can be incredibly valuable tools in preclinical
research. They allow scientists to get a much
quicker read on a drug's potential without having
to wait for those long -term clinical outcomes
to unfold. But I can also see how relying on
surrogate endpoints could be a bit tricky. What
if the correlation isn't as strong as we thought?
What if a drug improves the surrogate endpoint,
but it doesn't actually translate? to a meaningful
benefit for patients. You've hit on a very critical
point, and that's why the selection and validation
of surrogate endpoints is so important. Researchers
need to be really careful in choosing endpoints
that are truly reflective of that clinical outcome
they're interested in, and they need to back
up those choices with solid scientific evidence.
It sounds like a delicate balancing act, using
surrogate endpoints strategically to accelerate
research but also being very aware of their limitations
and potential pitfalls. Precisely. And that's
where those FDA and ICH guidelines that we discussed
earlier come back into play. Those guidelines
provide valuable guidance on how to choose and
validate surrogate endpoints appropriately, ensuring
that preclinical research is being conducted
rigorously and ethically. So those guidelines
are almost like a safety net, helping to make
sure that the research is on the right track
and that the conclusions drawn from it are sound.
Exactly. They really help to minimize bias, increase
transparency, and ultimately protect patients
by ensuring that only the most promising and
well -supported drugs actually move forward in
the development process. OK, that makes a lot
of sense. Now I know you've been diving deep
into those OPRND cases from our listener. Have
you come across any examples that really illustrate
these complexities of measuring efficacy and
navigating the world of surrogate endpoints?
Yeah, I have one case that really stood out,
involved a company developing a new drug for
Parkinson's disease. And they were using a rap
model that mimicked some of the key motor symptoms
of the disease, so things like tremors and rigidity.
So they were working with a model. that closely
reflected the clinical presentation of the disease
in humans. What were they looking at as their
measure of efficacy? They were actually taking
a multi -pronged approach, which is often, you
know, the most informative. They were observing
the rat's behavior. looking for improvements
in those motor symptoms, but they were also looking
deeper at the cellular level, specifically at
the dopamine -producing neurons in the brain.
Because those dopamine neurons are progressively
lost in Parkinson's disease, leading to those
very debilitating motor symptoms. Exactly. So
the researchers were measuring both behavioral
changes, the outward signs of improvement, but
also cellular changes, those underlying biological
mechanisms that are at play. That sounds like
a very comprehensive way to assess efficacy.
What did they find? Well, they actually observed
some pretty encouraging results. The drug significantly
improved the rat's motor function and then also
showed a protective effect on those crucial dopamine
neurons. Wow, that's really promising. It sounds
like a potential breakthrough for Parkinson's
treatment. It certainly did. But what's really
interesting about this case is how the researchers
approach the data. They were very cautious in
their interpretation, you know, acknowledging
that while the results were very exciting, they
were still just one piece of the puzzle. So they
weren't getting ahead of themselves, recognizing
that success in a rap model doesn't automatically
translate. to success in humans. Exactly. They
emphasize the importance of further research,
including clinical trials in human patients,
to confirm these initial findings and to fully
understand the drug's potential benefits and
risks. That's a great example of the scientific
process in action, celebrating the successes,
but also maintaining a critical eye and recognizing
the limitations of each step along the way. Precisely.
And it highlights the importance of transparency
and research being upfront about both the strengths
and weaknesses of a study and not overstating
the findings. You know, this honesty and transparency
are really essential for maintaining public trust
in the scientific process and ultimately ensuring
that only the most promising and well -supported
drugs advance to human trials. OK, so we've talked
about measuring efficacy in preclinical models,
but let's zoom out a bit. We've mentioned these
FDA and ICH guidelines several times. Can you
get a little more insight into the specific role
these guidelines play in shaping preclinical
research? What are some of the key areas that
they address? They do, you know, these guidelines,
they cover a really wide range of aspects, but
they're all aimed at ensuring the quality, reliability,
and ethical conduct of those preclinical studies.
So they're not just focused on those scientific
aspects, they're also addressing those ethical
dimensions of, you know, working with animal
models. Absolutely. Ethics is a paramount concern
in preclinical research, and you know, these
guidelines provide very clear guidance on how
to minimize the number of animals that are used,
how to ensure their welfare, and how to use you
know, appropriate anesthesia and analgesia to
minimize any pain or distress that they might
experience. That's reassuring to hear. It's good
to know that those ethical considerations are
really kind of woven into the fabric of that
research process. Yeah, they are. And beyond
the ethical aspects, you know, the guidelines
also address a lot of the nuts and bolts of designing
and conducting, you know, high quality studies.
OK, tell me more about that. What are some of
the specific areas that they delve into? Well,
they provide really detailed guidance on things
like selecting the right animal species and strain
for a particular study, making sure that the
animals are housed and cared for, you know, in
a way that really meets their specific needs
and even controlling for variables that could
influence the results of the experiment. So it's
kind of like... creating this standardized playbook
for pre -clinical research, making sure that
everyone is playing by the same rules and that
the results are as reliable and as meaningful
as possible. Exactly. The guidelines also delve
into statistical considerations, outlining appropriate
methods for analyzing data, and ensuring that
the conclusions that are drawn from the research
are statistically sound. It's not just about
collecting data. It's about analyzing it rigorously
and making sure that the conclusions are really
well supported by that evidence. Precisely. And
they even address data integrity, ensuring that
all data is accurately recorded, stored, and
reported. Wow. It sounds like these guidelines
really cover every aspect of preclinical research,
leaving no stone unturned in the quest for quality
and reliability. Yeah, they really do. They provide
a framework for conducting research that's both
scientifically rigorous and ethically sound and
ultimately, you know, that benefits everyone.
The researchers, the regulators, and most importantly,
the patients, you know, who will one day benefit
from the new drugs and treatments that emerge
from this research. Absolutely. It feels like
we've journeyed to the heart of drug discovery,
examining those crucial early stages where scientists
are gathering evidence and really building a
case for a drug's potential. Yeah, it's like
we've been working right alongside those researchers,
you know, piecing together that puzzle of preclinical
efficacy. Exactly. And speaking of puzzles, I
have one for you, Deep Diver. As you continue
exploring those research papers and those reports,
you're going to encounter a sea of data graphs,
tables, statistics. It can feel really overwhelming
at times. So what's the key to navigating all
that data and actually extracting meaningful
insights? That's a great question. And it really
all comes down to developing a critical eye for
data. So don't just passively absorb those numbers.
Question them, interrogate them, figure out what
they truly mean and what story they're really
telling. So it's not just about seeing a graph
that shows a drug -reducing tumor size. It's
about understanding how that data was collected,
what the units of measurement are, and whether
those findings are statistically significant
and reliable. Precisely. And remember, data can
be presented in so many different ways. And some
of those ways are much more transparent and informative
than others. So pay close attention to those
graphs and those tables. Are they clearly labeled?
do they accurately represent the data or are
they potentially misleading, you know, designed
to highlight certain findings while kind of obscuring
others? It's like being a detective, you know,
carefully examining the evidence for any signs
of manipulation or distortion. Exactly. And as
you kind of delve deeper into those OPR &D cases
that you sent, you'll really see how data interpretation
plays a really crucial role in real world research.
Sometimes the story that the data tells isn't
as straightforward as it might seem at first
glance. Oh, I can imagine. I bet those case studies
offer some pretty fascinating examples of how
data can be used and sometimes even misused in
the world of drug development. Oh, they do. One
case that really comes to mind involved a company
that was developing a new obesity drug. and their
pre -clinical studies in mice yielded some really
impressive results, you know, significant weight
loss, improved metabolic markers. It looked like
a potential blockbuster. So it sounds like they
had stumbled upon a miracle cure. What happened?
Well, when the drug moved into human trials,
the results were much less impressive. The weight
loss was really minimal, and there were actually
some concerning side effects. And it turned out
that the company had basically cherry -picked
their preclinical data, highlighting only the
positive findings while downplaying or even ignoring
the negative ones. Wow. That's not only misleading,
it's potentially really dangerous. Patients could
be given false hope, and resources could be wasted
pursuing a drug that's ultimately ineffective
or even harmful. Yeah, you're absolutely right.
And this case really underscores the importance
of transparency and rigor in preclinical research.
It's crucial to report all the data, both the
positive and the negative, and to be upfront
about the limitations of the studies. This honesty
and this transparency are absolutely essential
for maintaining public trust in the scientific
process and ensuring that only the most promising
and well -supported drugs actually advance to
those human trials. It's a good reminder that
even in the world of science, where objectivity
is paramount, There can be those subjective biases
and agendas at play. We need to be aware of those
potential biases and approach data with a healthy
dose of skepticism. Absolutely. And that's where
critical thinking really comes in as you read
those research papers. Don't just accept those
conclusions at face value. Dig deeper. Ask questions.
Consider the source of the information and any
potential conflicts of interest that might be
there. It's about being an active participant
in that process of knowledge acquisition. You're
not just a passive recipient of information.
Precisely. And remember knowledge is power by
really understanding how preclinical efficacy
models work, recognizing both their strengths
and their limitations, and learning to interpret
data critically. You're empowering yourself to
make better, more informed decisions. about your
health and your well -being. And that's what
this whole deep dive is all about, empowering
you, a deep diver, to navigate this really complex
world of science and medicine with confidence
and a discerning eye. It's about giving you the
tools you need to understand not just what the
research says, but also how that research was
conducted, what it truly means, and how it might
impact your life. We've covered a lot of ground
in this deep dive, from those fundamentals of
preclinical models to the nuances of data interpretation
and the crucial role of regulatory oversight.
But as with any deep dive, there's always more
to explore. There is. And as you continue your
exploration, just remember that the world of
science is constantly evolving. New discoveries
are being made. New technologies are emerging.
And our understanding of the human body and disease
is constantly deepening. So keep asking questions.
Keep challenging those assumptions. and keep
that critical thinking cap firmly in place. And
never lose sight of the ultimate role of all
this research to improve human health, to alleviate
suffering, and to extend the reach of human potential.
On that note, we'll leave you with a final thought.
We've talked a lot about predicting a drug's
effectiveness in humans, but what about predicting
its impact on the broader environment as we develop
these new drugs? We need to consider not only
their effects on human health, but also their
potential impact on those ecosystems we all share.
That's a challenge for science and for society
as a whole, and it's something worth pondering
as we strive to create a healthier and more sustainable
future for everyone. That's a really profound
thought and a fitting reminder that our pursuit
of scientific knowledge should always be guided
by a sense of responsibility and a commitment
to the well -being of both humanity and the planet
we all call home.